| Company | Value | Change | %Change |
|---|
The pharmaceutical company informed the stock exchanges in a filing that it has received marketing authorisation for Southeast Asia’s largest pharmaceutical market, Indonesia, for its anticoagulant ‘Enoxaparin’.
Indonesia has permitted Venus Remedies to market Enoxaparin in pre-filled syringes across all major strengths.
Anticoagulants, also known as blood thinners, are used to prevent blood clots from forming. Enoxaparin helps prevent the formation of blood clots in the legs for patients who are bedridden or undergoing procedures such as hip replacement, knee replacement, or abdominal surgery.The approval of marketing its Enoxaparin in Indonesia reinforces Venus Remedies’ presence in the Southeast Asian country while aligning with its broader expansion strategy in the region.
Shares of Venus Remedies rallied as much as 2.76% to hit an intraday high of ₹370 apiece on the BSE. However, the stock pared some of its early gains to trade 0.22% lower at ₹359.25 per piece on the stock exchange at 1:58 pm.For the quarter ended December 31, 2024, Venus Remedies reported a net profit of ₹19.6 crore, rising by a robust 186% on a YoY basis from ₹6.85 crore witnessed in the same period last year.
Its consolidated revenue from operations grew 23.3% YoY to ₹176.86 crore in Q3FY25 as opposed to ₹143.4 crore in the corresponding quarter of the previous fiscal.
Last month, on January 20, Venus Remedies successfully renewed its European Good Manufacturing Practices (GMP) certification from Infarmed, Portugal’s national authority of medicines and health products.
The certification covered the company’s manufacturing facility for cephalosporin, carbapenem and lyophilized injectable oncology formulations, reaffirming its commitment to delivering world-class pharmaceutical products to the European market.
Catch live market updates with CNBC-TV18.com’s blog
